Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseases
The introduction of anti-tumor necrosis factor (TNF) therapies has dramatically improved the treatment of immune-mediated inflammatory diseases and provides treatment options for patients who do not respond to conventional disease-modifying antirheumatic drugs. However, the use of anti-TNF therapies still needs to be optimized. Dropoff rates, patients' lack of response, and toxicity are issues that need to be addressed to render these therapies more effective for more patients. 